November 6, 2025 – Talk Bio

Novo Nordisk Ups the Stakes With $10B Bid for Metsera, Surpassing Pfizer’s Offer

23 hours ago talkbio0Tagged antitrust litigation, bidding war, contingent value right, Drug Industry, Metsera, Novo Nordisk, Pfizer

Novo Nordisk; Pfizer; Metsera; bidding war; acquisition; $10 billion; contingent value right; pharmaceutical industry; antitrust litigation

Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results

23 hours ago talkbio0Tagged Agonist, Amylin, Clinical Development, Eli, Eli Lilly, Eloralintide, Obesity Drug, Phase 3 Clinical Trials, Weight Loss

Eli Lilly; eloralintide; amylin agonist; obesity drug; Phase III trial; weight loss; clinical development

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

1 day ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

TriNetX Achieves Record as the Most Cited Real-World Electronic Health Record Dataset in Peer-Reviewed Research

1 day ago talkbio0Tagged Citation, Clinical Trials, Data Analytics, Electronic Health Records, global network, Medical Research activity, Peer-Reviewed Research, Rare Diseases, real-world data, TriNetX

TriNetX; real-world data; electronic health records; peer-reviewed research; citations; medical research; data analytics; global network; rare disease; clinical trials

Delaware Court Denies Pfizer’s Bid to Block Novo Nordisk-Metsera Deal

1 day ago talkbio0Tagged Antitrust, Delaware Court, merger agreement, Metsera, Nordisk, Obesity, Pfizer, restraining order, Transitory, United States Federal Trade Commission

Delaware Court; Pfizer; Novo Nordisk; Metsera; temporary restraining order; merger agreement; antitrust; FTC; obesity drugs

Oura Health’s Healthcare Ambitions Materialize with $11 Billion Valuation and Expansion Plans

1 day ago talkbio0Tagged expansion, Generalized, Healthcare technology, Oura, Oura Ring, personalized health services, Preventive Health Services, Series E funding, valuation, wearables market

Oura; Oura Ring; healthcare technology; Series E funding; $11B valuation; AI health features; wearables market; global expansion; preventive health; personalized health services

Arena BioWorks Shuts Down After Investors Withdraw Support for Bold Biotech Model

1 day ago talkbio0Tagged Arena BioWorks, Biomedical Research, concerns, Funding, funding environment, Industry, investor, layoffs, Policy, shutdown, Uncertainty

Arena BioWorks; biotech shutdown; policy uncertainty; funding environment; biomedical research; $500 million funding; layoffs; biotech industry; investor concerns

FluoGuide Strengthens Leadership to Drive Clinical and Regulatory Advancements

1 day ago talkbio0Tagged board of directors, Camilla Harder Hartvig, Changing, Chief Operating Officer, Clinical Development, Donna Haire, FluoGuide, Leadership, precision cancer, regulatory approval

FluoGuide; leadership changes; Donna Haire; Chief Operating Officer; Camilla Harder Hartvig; Board of Directors; FG001; clinical development; regulatory approval; precision cancer surgery

Santen Announces Completion of Share Buyback

1 day ago talkbio0Tagged buyback, Dosage Forms, equity buyback, Japanese language, Occupational activity of managing finances, repurchase, Santen, shareholder value

Santen Pharmaceutical; share buyback; repurchase; equity buyback; shareholder value; Japanese pharmaceuticals; financial management

Closed Loop Medicine Secures Additional Key GLP-1 Patent for Its AI-Based Dosing Platform: Powering Personalized, Direct-to-Patient Therapies

2 days ago talkbio0Tagged adaptive dosing, AI-based, Closed Loop Medicine, dosing, Glucagon-Like Peptide 1, incretin drugs, Legal patent, personalized therapies, semaglutide, WeDosify

Closed Loop Medicine; GLP-1; patent; AI-based dosing; personalized therapies; semaglutide; incretin drugs; WeDosify; adaptive dosing; direct-to-patient